Chimeric canine anti-CD20 antibody

Patent metadata

Field	Value
Publication number	US-10519244-B2
Application number	US-201716073927-A
Country	US
Kind code	B2
Filing date	Feb 10, 2017
Priority date	Feb 18, 2016
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hodgkins B-cell lymphoma in dogs.

First claim

What is claimed is:

1. An antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3.

2. The antibody of claim 1 , wherein the antibody specifically binds to canine CD20.

3. The antibody of claim 1 , wherein the antibody comprises a light chain (LC) whose amino acid sequence is that given in SEQ ID NO: 10, and a heavy chain (HC) whose amino acid sequence is that given in SEQ ID NO: 1.

4. The antibody of claim 3 , wherein the antibody specifically binds to canine CD20.

5. The antibody of claim 1 , wherein the antibody comprises two light chains (LC) each having an amino acid sequence that is given in SEQ ID NO: 10, and two heavy chains (HC) each having an amino acid sequence that is given in SEQ ID NO: 1.

6. The antibody of claim 5 , wherein the antibody specifically binds to canine CD20.

7. A method of treating lymphoma in a canine patient, comprising administering to a lymphoma cancer canine patient in need of such treatment an effective amount of an antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3, wherein the antibody specifically binds to canine CD20.

8. The method according to claim 7 wherein the antibody comprises a light chain (LC) whose amino acid sequence is that given in SEQ ID NO: 10, and a heavy chain (HC) whose amino acid sequence is that given in SEQ ID NO: 1.

9. A kit, comprising a pharmaceutical composition, comprising an antibody which specifically binds to canine CD20, with one or more pharmaceutically acceptable carriers, diluents, or excipients;
wherein the antibody which specifically binds to canine CD20 comprises a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3.

10. The antibody of claim 4 , wherein the antibody binds to protein A.

Assignees

• Elanco Us Inc

Inventors

• Pancook James David

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/1271

  Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G) · CPC title